Bacterial and Fungal Infections

The pattern of bacterial infections globally is changing due to global warming, increasing antimicrobial resistance, and population migration. As a result, multidrug-resistant bacteria are increasingly seen in Europe. Immunotherapies, including monoclonal antibodies, checkpoint inhibition, T cell-based immunotherapies and cytokine therapy offer promise as alternative approaches. Fungal infections, particularly invasive infections, are among the most difficult human diseases to manage. Challenges in their treatment include toxicity, interactions, restricted routes of administration, and drug resistance. Therapies in early development include, 2 glucan synthesis inhibitors; fourth-generation azoles; agents with intracellular targets and neurapheresis, a filtration device used as adjunctive therapy for cryptococcosis. Choosing clinical candidates from early studies will be challenging.

Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.